Healthcare Stock Surges 11% on Strong ANDA Pipeline and 385% Branded Generics Growth in Q4

Synopsis: The share jumps 11 percent on strong Q4 performance, driven by robust ANDA (Abbreviated New Drug Application) pipeline and 385 percent growth in branded generics, signalling strong future growth visibility.

The share of this company, which is a research-driven company focused on developing and manufacturing complex generics, with a strong presence in the US, Canada, and regulated markets, came into focus after strong Q4 segment performance.

With a market capitalization of Rs 4,831 crore, Senores Pharmaceuticals Ltd’s shares on Friday made a day high of Rs 1,062 per share, up 11.2 percent from its previous day’s close price of Rs 954.80 per share. The share of this company gave a negative return of 94 percent over the last year.

Results Overview

QoQ View: The revenue from operations grew by 2.3 percent to Rs 175 crore in Q4 FY26 from Rs 171 crore in Q3 FY26 (Dec 2025). EBIDT saw a slight decrease of 5.7 percent to Rs 47.5 crore from Rs 50.4 crore in the previous quarter. However, net profit increased by 9.2 percent to Rs 36.7 crore from Rs 33.6 crore, while the EPS remained stable at Rs 6.86 per share compared to Rs 6.87 in Q3 FY26.

YoY View: The revenue from operations grew by 53 percent to Rs 175 crore in Q4 FY26 (Mar 2026) from Rs 114 crore in Q4 FY25 (Mar 2025), and EBIDT grew by 144 percent to Rs 47.5 crore in Q4 FY26 from Rs 19.4 crore in Q4 FY25. Accompanied by a net profit growth of 77 percent to Rs 36.7 crore in Q4 FY26 from Rs 18.0 crore in Q4 FY25, resulting in an EPS growth of 77 percent to Rs 6.86 per share in Q4 FY26.

Fiscal year comparison: Revenue from operations increased from Rs 398 crore in FY25 to Rs 633 crore in FY26, up 59 percent year-on-year. Profit before tax rose from Rs 71 crore in FY25 to Rs 159 crore in FY26, a jump of 124 percent. Profit after tax improved from Rs 58 crore in FY25 to Rs 122 crore in FY26, up 110.3 percent. Earnings per share increased from Rs 12.72 in FY25 to Rs 25.02 in FY26, reflecting a growth of 97 percent.

Q4 Business Highlight

Cash flow from operations improved significantly to Rs 75 crore in FY26, indicating a strong turnaround in operational efficiency. Better EBITDA-to-cash conversion reflects tighter working capital management and improved execution, supporting healthier liquidity generation and strengthening overall financial flexibility for future expansion plans.

The regulated markets pipeline remains robust with 51 approved ANDAs covering 151 strengths. Additionally, more than 30 ANDAs are yet to be launched, and 27 are under development across 65 plus strengths. This strong pipeline provides multi-year revenue visibility and supports sustained growth momentum in regulated geographies.

Emerging markets continued steady performance in FY26 with revenue growth of around 13 percent year-on-year and EBITDA margin near 12 percent, supported by a focused product mix. Branded generics delivered exceptional momentum, surging about 385 percent year-on-year, driven by increasing acceptance across multi-specialty and specialty hospitals, strengthening long-term scalability.

Segment performance

• Regulated Markets driving core growth through ANDA pipeline: Regulated Markets revenue jumped to Rs 117.8 crore in Q4FY26 from Rs 64.3 crore in Q4FY25, up 83 percent YoY. FY26 revenue stood at Rs 427.4 crore versus Rs 244.8 crore, reflecting strong 74.6 percent growth, supported by expanding ANDA-led product approvals and launches.
• Strong visibility from expanding product portfolio:  Growth momentum in regulated markets is backed by a widening ANDA pipeline, which continues to strengthen multi-year revenue visibility and supports scaling of complex generic offerings in global markets.
• Branded Generics emerging as high-growth driver: Branded Generics revenue surged 132.4 percent YoY in Q4FY26 to Rs 9.4 crore and rose sharply by 385.3 percent in FY26 to Rs 40 crore versus Rs 8.2 crore, reflecting rapid traction and hospital acceptance.
• Diversified segments supporting overall sustainability:  Emerging Markets grew 25.8 percent in Q4FY26 and 19.7 percent in FY26, while total income rose 57.9 percent in Q4FY26 to Rs 189.7 crore, indicating balanced growth across geographies and product segments.

About the Business

Senores Pharmaceuticals Ltd is an Ahmedabad-based, research-driven pharmaceutical company incorporated in 2017, specializing in the development and manufacturing of complex generics, specialty, and critical care injectables. It has a global presence, exporting to 49+ countries and operating 3 manufacturing facilities (including USFDA-approved sites) in the USA and India. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Healthcare Stock Surges 11% on Strong ANDA Pipeline and 385% Branded Generics Growth in Q4 appeared first on Trade Brains.